Abstract:IMPORTANCE Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) may have different effects on cardiovascular (CV) events in patients with diabetes mellitus (DM). OBJECTIVE To conduct ameta-analysis to separately evaluate the effects of ACEIs and ARBs on all-cause mortality, CV deaths, and major CV events in patients with DM. DATA SOURCES Data sources included MEDLINE (1966-2012), EMBASE (1988-2012), the Cochrane Central Register of Controlled Trials, conference proceedings, and article reference lists. STUDY SELECTION We included randomized clinical trials reporting the effects of ACEI and ARB regimens for DM on all-cause mortality, CV deaths, and major CV events with an observation period of at least 12 months. Studies were excluded if they were crossover trials. DATA EXTRACTION AND SYNTHESIS Dichotomous outcome data from individual trials were analyzed using the risk ratio (RR) measure and its 95% CI with random-effects models. We estimated the difference between the estimates of the subgroups according to tests for interaction. We performed meta-regression analyses to identify sources of heterogeneity. MAIN OUTCOMES AND MEASURES Primary end points were all-cause mortality and death from CV causes. Secondary end points were the effects of ACEIs and ARBs on major CV events. RESULTS Twenty-three of 35 identified trials compared ACEIs with placebo or active drugs (32 827 patients) and 13 compared ARBs with no therapy (controls) (23 867 patients). When compared with controls (placebo/active treatment), ACEIs significantly reduced the risk of all-cause mortality by 13%(RR, 0.87; 95% CI, 0.78-0.98), CV deaths by 17%(0.83; 0.70-0.99), and major CV events by 14%(0.86; 0.77-0.95), including myocardial infarction by 21% (0.79; 0.65-0.95) and heart failure by 19% (0.81; 0.71-0.93). Treatment with ARBs did not significantly affect all-cause mortality (RR, 0.94; 95% CI, 0.82-1.08), CV death rate (1.21; 0.81-1.80), and major CV events (0.94; 0.85-1.01) with the exception of heart failure (0.70; 0.59-0.82). Both ACEIs and ARBs were not associated with a decrease in the risk for stroke in patients with DM. Meta-regression analysis showed that the ACEI treatment effect on all-cause mortality and CV death did not vary significantly with the starting baseline blood pressure and proteinuria of the trial participants and the type of ACEI and DM. CONCLUSIONS AND RELEVANCE Angiotensin-converting enzyme inhibitors reduced all-cause mortality, CV mortality, and major CV events in patients with DM, whereas ARBs had no benefits on these outcomes. Thus, ACEIs should be considered as first-line therapy to limit excess mortality and morbidity in this population.

ADRs and Clinical Rational Use of Angiotensin Converting Enzyme Inhibitor

ADR Case Reports:Analysis of 810 Cases

ADRs monitoring and analysis of cardiovascular drugs

A Retrospective Study on 990 ADR Case Reports in Our Hospital During 2002～2005

Carbapenem Antibacterial Drugs Induced Adverse Drug Reaction

Adverse drug reaction reports in department of cardiology of a 3 A hospital:an analysis of 572 cases

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.

Evaluation of the Correlation Between ACEI and Renal Function

Acei/Arb Therapy for Iga Nephropathy: A Meta Analysis of Randomised Controlled Trials

Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective

Analysis of the Adverse Drug Reactions Reports of 139 Cases

Study on 990 Cases of Adverse Drug Reaction

Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis

ACE-Inhibitor Related Angioedema Is Not Sufficiently Reported to the Danish Adverse Drug Reactions Database

Analysis on 342 Repors and Discssion about the Methods of Prevention with Adverse Drug Reactions/events

Adverse Drug Reaction Reports in a 3A Hospital During 2005-2011:An Analysis of 10 097 Cases

Analysis of 136 ADRs Induced by Chinese Patent Medicine

A General Introduction of Clinical Application of Angiotension Converting Enzyme Inhibitors

Adverse Reaction of Commonly Used Anti-Hypertensives and Safety Countermeasure on Clinic

Retrospective Analysis of New and Severe ADR Case Reports in Our Hospital from 2002 to 2006